Josh is the CEO of Tulavi Therapeutics. He has worked in healthcare and medical devices as a physician, entrepreneur, investor, and advisor for over 20 years. Josh was most recently the CEO of SIA Health, where he led the company through its Series B raise, commercial growth, and subsequent acquisition by Integra LifeSciences. Prior to SIA, Josh was the Chief Medical Officer for EnClear Therapies, where he helped develop a novel approach to treating CSF-mediated neurodegenerative diseases. Before EnClear he was a medical director for Medtronic following the acquisition of PEAK Surgical, where he was an early employee. Josh holds a BS in Chemical Engineering from Georgia Tech, a MD from the Medical College of Georgia, and MBA from the Sloan School of Management at MIT.
Josh is the CEO of Tulavi Therapeutics. He has worked in healthcare and medical devices as a physician, entrepreneur, investor, and advisor for over 20 years. Josh was most recently the CEO of SIA Health, where he led the company through its Series B raise, commercial growth, and subsequent acquisition by Integra LifeSciences. Prior to SIA, Josh was the Chief Medical Officer for EnClear Therapies, where he helped develop a novel approach to treating CSF-mediated neurodegenerative diseases. Before EnClear he was a medical director for Medtronic following the acquisition of PEAK Surgical, where he was an early employee. Josh holds a BS in Chemical Engineering from Georgia Tech, a MD from the Medical College of Georgia, and MBA from the Sloan School of Management at MIT.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy